GlassScriptPhysician profile
Vincent J Ross
NPI 1366525339
$1,077.49
in general payments reported to CMS, 2019-2025
16 companies · $112 in 2025
The $112 reported for 2025 was less than what a typical Sports Medicine (Family Medicine) provider received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $208 · 2020: $319 · 2021: $94.35 · 2022: $148 · 2023: $78.79 · 2024: $117 · 2025: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $307.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Therapeutics, INC. | $280.15 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $176.52 | 2019-2024 | Euflexxa |
| Novo Nordisk INC | $157.17 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Eisai INC. | $82.36 | 2020-2021 | |
| Fidia Pharma USA INC. | $81.84 | 2019-2025 | Hymovis, Triluron |
| Horizon Therapeutics Plc | $58.08 | 2019 | |
| Bioventus LLC | $37.25 | 2019-2022 | |
| Lilly USA, LLC | $30.41 | 2022-2024 | Zepbound, Jardiance |
| International Rehabilitative Sciences, INC | $28.38 | 2025 | Rs-4i Plus With Intersperse |
| Pfizer INC. | $25.21 | 2019-2021 | |
| Allergan, INC. | $23.53 | 2020 | |
| Amgen INC. | $23.32 | 2024 | Otezla, Repatha |
| Ultragenyx Pharmaceutical INC. | $22.92 | 2022 | |
| Abbvie INC. | $17.96 | 2024 | |
| Idorsia Pharmaceuticals US INC | $17.63 | 2023 | Quviviq |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biodelivery Sciences International, INC. | $14.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.